A. Bosanquet

发表

Assessment of fl udarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial

D. Catovsky, D. Oscier, E. Matutes, 2007 .

Assessment of fl udarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial

D. Catovsky, D. Oscier, E. Matutes, 2007 .

The use of individualized tumor response testing in treatment selection: second randomization results from the LRF CLL4 trial and the predictive value of the test at trial entry

D. Catovsky, E. Matutes, S. Richards, 2012, Leukemia.

Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial

T Hamblin, A. Pettitt, D. Catovsky, 2007, The Lancet.

Mutation of p53 and consecutive selective drug resistance in B-CLL occurs as a consequence of prior DNA-damaging chemotherapy

B. Dörken, P. Daniel, I. Sturm, 2003, Cell Death and Differentiation.

Ex vivo assessment of drug response by differential staining cytotoxicity (DiSC) assay suggests a biological basis for equality of chemotherapy irrespective of age for patients with chronic lymphocytic leukaemia

A. Bosanquet, MI Bosanquet, 2000, Leukemia.

Methylprednisolone in advanced chronic lymphocytic leukaemia: rationale for, and effectiveness of treatment suggested by DiSC assay.

D. Catovsky, S. McCann, G. Crotty, 1995, Acta haematologica.

Bax expression correlates with cellular drug sensitivity to doxorubicin, cyclophosphamide and chlorambucil but not fludarabine, cladribine or corticosteroids in B cell chronic lymphocytic leukemia

B. Dörken, P. Daniel, F. Essmann, 2002, Leukemia.